American Journal of Ophthalmology
Volume 149, Issue 1 , Pages 10-17.e2, January 2010

From the Laboratory to the Clinic: Molecular Genetic Testing in Pediatric Ophthalmology

  • Arlene V. Drack

      Affiliations

    • Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, Iowa City, Iowa
    • Corresponding Author InformationInquiries to Arlene V. Drack, Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242
  • ,
  • Scott R. Lambert

      Affiliations

    • Department of Ophthalmology, Emory University, Atlanta, Georgia
  • ,
  • Edwin M. Stone

      Affiliations

    • Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, Iowa City, Iowa
    • Howard Hughes Medical Institute, Chevy Chase, Maryland

Accepted 31 August 2009.

Purpose

To review the current state of molecular genetic testing as it relates to pediatric ophthalmology and to discuss its uses.

Design

Review and evaluation of available molecular genetic testing.

Methods

Literature review and discussion of testing in practice based on the authors' clinical and laboratory experience.

Results

Fee-for-service testing for many genetic eye diseases now is available. A report is always generated for fee-for-service testing. Detection of DNA variants in genes known to cause eye disease must be interpreted taking into account the variability of the human genome, the presence of benign variants (polymorphisms), and the carrier frequency of recessive alleles. Negative results in genetic testing are helpful in some disorders for which most of the causative genes are known and many disease-causing variants have already been reported, but are less helpful in those that currently have many undiscovered causative genes or novel mutations. Research-based testing also is available, but does not always yield a result. Patients with RPE65-associated Leber congenital amaurosis may be eligible for the current gene therapy trial. Patients with a variety of disorders may benefit from improved surveillance if their genetic diagnosis is known.

Conclusions

Entry into the genetic testing system often is via the patient's ophthalmologist. Collaboration with geneticists and genetic counselors, use of web sites to keep up with the ever-changing availability and detection rates, and knowledge of clinical trials, when combined with excellent clinical diagnosis, can improve diagnosis and allow eligible patients to participate in treatment trials.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9394(09)00664-3

doi:10.1016/j.ajo.2009.08.038

American Journal of Ophthalmology
Volume 149, Issue 1 , Pages 10-17.e2, January 2010